It has been 12 years since the US Food & Drug Administration convened an advisory committee review of the Risk Evaluation & Mitigation Strategy for the acne drug isotretinoin, and in many ways, it was business as usual: dermatologists advocated for loosening of restrictions, with FDA and generic drug sponsors pushing back against too much change.
That was certainly the scene during the last advisory committee review of iPLEDGE in 2011, when committee members encouraged FDA to pull back what is arguably the most restrictive distribution program for any teratogen, including thalidomide
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?